+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Castrate-resistant Prostate Cancer Market Size, Share & Trends Analysis Report by Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), by Region, and Segment Forecasts, 2020-2027

  • ID: 5230429
  • Report
  • November 2020
  • Region: Global
  • 90 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Astellas Pharma, Inc.
  • Bayer AG
  • Pfizer Inc.
  • Sanofi
  • MORE
Castrate-resistant Prostate Cancer Market Growth & Trends

The global castrate-resistant prostate cancer market size is expected to reach USD 16.2 billion by 2027. The market is expected to expand at a CAGR of 8.4% from 2020 to 2027. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.

In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.

The hormonal therapy segment dominated the market and held the largest revenue share of 83.1% in 2019. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.

North America’s dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.

The presence of prominent players such as Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma, Inc.; and Bayer AG in this market space significantly diminishes the opportunities of a new entry as it is difficult to match the high capital requirements. Key players are investing highly in the development of new molecules to maintain their presence in the market and acquire market share.

Castrate-resistant Prostate Cancer Market Report Highlights
  • Prostate cancer is the highest prevalent cancer in men. 1 in 9 men are diagnosed with prostate cancer.
  • Within 3 years of diagnosis, 10-50% of overall prostate cancer cases develop into metastatic castrate-resistant prostate cancer.
  • The recommendation of products from healthcare authorities is expected to increase the sales of the drug, thereby fueling market growth. For instance, Provenge is recommended by the Society for Immunotherapy of Cancer, the National Comprehensive Cancer Network, and the American Urological Association.
  • Australia and New Zealand have the highest prevalence rate of the disease, followed by North America and Europe.
  • In Asia Pacific, the market is likely to witness the fastest CAGR of 11.5% from 2020 to 2027.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma, Inc.
  • Bayer AG
  • Pfizer Inc.
  • Sanofi
  • MORE
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources & third-party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.8. Commodity Flow Analysis
1.9. Approach: Commodity Flow Approach
1.10. List of Secondary Sources
1.11. List of Abbreviations
1.12. Objective
1.13. Objective 1
1.14. Objective 2
1.15. Objective 3
1.16. Objective 4

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Castrate-Resistant Prostate Cancer Market Variables, Trends & Scope
3.1. Castrate-Resistant Prostate Cancer Market Lineage outlook
3.1.1. Parent market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. User Perspective Analysis
3.4. Regulatory Framework
3.5. Market Dynamics
3.5.1. Market driver analysis
3.5.1.1. Rising prevalence of castrate-resistant prostate cancer
3.5.1.2. Increasing technological advancements
3.5.1.3. Rising adoption of treatment
3.5.2. Market restraint analysis
3.5.2.1. Lack of standard therapy
3.6. Castrate-Resistant Prostate Cancer Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat from New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTEL Analysis
3.6.2.1. Political Landscape
3.6.2.2. Environmental Landscape
3.6.2.3. Social Landscape
3.6.2.4. Technology Landscape
3.6.2.5. Legal Landscape

Chapter 4. Castrate-Resistant Prostate Cancer Market: Therapy Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Therapy Market Share Analysis, 2019 & 2027
4.3. Therapy Dashboard
4.4. Castrate-Resistant Prostate Cancer Market, By Therapy, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
4.5.1. Chemotherapy
4.5.1.1. Chemotherapy market, 2016 - 2027 (USD Million)
4.5.2. Hormonal Therapy
4.5.2.1. Hormonal therapy market, 2016 - 2027 (USD Million)
4.5.3. Immunotherapy
4.5.3.1. Immunotherapy market, 2016 - 2027 (USD Million)
4.5.4. Radiotherapy
4.5.4.1. Radiotherapy market, 2016 - 2027 (USD Million)

Chapter 5. Castrate-resistant Prostate Cancer Market: Segment Analysis, By Region, 2016 - 2027 (USD Million)
5.1 Castrate-resistant Prostate Cancer Market, Market Share by Region, 2019 & 2027
5.1.1 North America
5.1.1.1 North America market estimates and forecast, 2015 - 2027 (USD Million)
5.1.1.2 U.S.
5.1.1.2.1 U.S. market estimates and forecast, 2015 - 2027 (USD Million)
5.1.1.3 Canada
5.1.1.3.1 Canada market estimates and forecast, 2015 - 2027 (USD Million)
5.1.2 Europe
5.1.2.1 Europe market estimates and forecast, 2015 - 2027 (USD Million)
5.1.2.2 U.K.
5.1.2.2.1 U.K. market estimates and forecast, 2015 - 2027 (USD Million)
5.1.2.3 Germany
5.1.2.3.1 Germany market estimates and forecast, 2015 - 2027 (USD Million)
5.1.2.4 France
5.1.2.4.1 France market estimates and forecast, 2015 - 2027 (USD Million)
5.1.2.5 Spain
5.1.2.5.1 Spain market estimates and forecast, 2015 - 2027 (USD Million)
5.1.2.6 Italy
5.1.2.6.1 Italy market estimates and forecast, 2015 - 2027 (USD Million)
5.1.2.7 Russia
5.1.2.7.1 Russia market estimates and forecast, 2015 - 2027 (USD Million)
5.1.3 Asia Pacific
5.1.3.1 Asia Pacific market estimates and forecast, 2015 - 2027 (USD Million)
5.1.3.2 Japan
5.1.3.2.1 Japan market estimates and forecast, 2015 - 2027 (USD Million)
5.1.3.3 China
5.1.3.3.1 China market estimates and forecast, 2015 - 2027 (USD Million)
5.1.3.4 India
5.1.3.4.1 India market estimates and forecast, 2015 - 2027 (USD Million)
5.1.3.5 South Korea
5.1.3.5.1 South Korea market estimates and forecast, 2015 - 2027 (USD Million)
5.1.3.6 Singapore
5.1.3.6.1 Singapore market estimates and forecast, 2015 - 2027 (USD Million)
5.1.3.7 Australia
5.1.3.7.1 Australia market estimates and forecast, 2015 - 2027 (USD Million)
5.1.4 Latin America
5.1.4.1 Latin America market estimates and forecast, 2015 - 2027 (USD Million)
5.1.4.2 Brazil
5.1.4.2.1 Brazil market estimates and forecast, 2015 - 2027 (USD Million)
5.1.4.3 Mexico
5.1.4.3.1 Mexico market estimates and forecast, 2015 - 2027 (USD Million)
5.1.4.4 Argentina
5.1.4.4.1 Argentina market estimates and forecast, 2015 - 2027 (USD Million)
5.1.6 Middle East and Africa
5.1.6.1 Middle East & Africa market estimates and forecast, 2015 - 2027 (USD Million)
5.1.6.2 South Africa
5.1.6.2.1 South Africa market estimates and forecast, 2015 - 2027 (USD Million)
5.1.6.3 UAE
5.1.6.3.1 UAE market estimates and forecast, 2015 - 2027 (USD Million)
5.1.6.4 Saudi Arabia
5.1.6.4.1 Saudi Arabia market estimates and forecast, 2015 - 2027 (USD Million)

Chapter 6. Company Profiles
6.1. Recent developments & impact analysis, by key market participants
6.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
6.3. Public Companies
6.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
6.3.2. Competitive dashboard analysis
6.3.3. Market differentiators
6.4. Private Companies
6.5. Company Profiles
6.5.1. Sanofi
6.5.1.1. Company Overview
6.5.1.2. Financial Performance
6.5.1.3. Product Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Johnson & Johnson Services Inc.
6.5.2.1. Company Overview
6.5.2.2. Financial Performance
6.5.2.3. Product Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. Pfizer Inc.
6.5.3.1. Company Overview
6.5.3.2. Financial Performance
6.5.3.3. Product Benchmarking
6.5.3.4. Strategic Initiatives
6.5.4. Astellas Pharma, Inc.
6.5.4.1. Company Overview
6.5.4.2. Financial Performance
6.5.4.3. Product Benchmarking
6.5.4.4. Strategic Initiatives
6.5.5. Bayer AG
6.5.5.1. Company Overview
6.5.5.2. Financial Performance
6.5.5.3. Product Benchmarking
6.5.5.4. Strategic Initiatives

List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Regulatory Framework
Table 4 Global Castrate-resistant Prostate Cancer Market, By Region, 2016-2027 (USD Million)
Table 5 Global Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 6 North America Castrate-resistant Prostate Cancer Market, By Country, 2016-2027 (USD Million)
Table 7 North America Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 8 U.S. Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 9 Canada Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 10 Europe Castrate-resistant Prostate Cancer Market, By Country, 2016-2027 (USD Million)
Table 11 Europe Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 12 U.K. Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 13 Germany Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 14 France Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 15 Spain Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 16 Italy Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 17 Russia Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 18 Asia Pacific Castrate-resistant Prostate Cancer Market, By Country, 2016-2027 (USD Million)
Table 19 Asia Pacific Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 20 China Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 21 Japan Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 22 India Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 23 South Korea Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 24 Singapore Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 25 Australia Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 26 Latin America Castrate-resistant Prostate Cancer Market, By Country, 2016-2027 (USD Million)
Table 27 Latin America Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 28 Brazil Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 29 Mexico Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 30 Argentina Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 31 MEA Castrate-resistant Prostate Cancer Market, By Country, 2016-2027 (USD Million)
Table 32 MEA Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 33 South Africa Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 34 UAE Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)
Table 35 Saudi Arabia Castrate-resistant Prostate Cancer Market, By Therapy, 2016-2027 (USD Million)

List of Figures
FIG. 1 Castrate-resistant Prostate Cancer Market Segmentation
FIG. 2 Market Research Process
FIG. 3 Information Procurement
FIG. 4 Primary Research Pattern
FIG. 5 Market Research Approaches
FIG. 6 Value-Chain-Based Sizing & Forecasting
FIG. 7 QFD Modeling for Market Share Assessment
FIG. 8 Market Formulation & Validation
FIG. 9 Castrate-resistant Prostate Cancer Market Snapshot
FIG. 10 Castrate-resistant Prostate Cancer Market Driver Impact
FIG. 11 Castrate-resistant Prostate Cancer Market Restraint Impact
FIG. 12 Penetration and Growth Prospect Mapping
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 SWOT Analysis, By Factor (Political & Legal Economic and Technological)
FIG. 15 Therapy Market Share Analysis, 2019 & 2027
FIG. 16 Therapy Dashboard
FIG. 17 Chemotherapy Market, 2016 - 2027 (USD Million)
FIG. 18 Hormonal Therapy Market, 2016 - 2027 (USD Million)
FIG. 19 Immunotherapy Derivatives Market, 2016 - 2027 (USD Million)
FIG. 20 Radiotherapy Market, 2016 - 2027 (USD Million)
FIG. 21 Castrate-resistant Prostate Cancer Market, Market Share by Region, 2019 & 2027
FIG. 22 North America
FIG. 23 North America Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 24 U.S.
FIG. 25 U.S. Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 26 Canada
FIG. 27 Canada Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 28 Europe
FIG. 29 Europe Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 30 U.K.
FIG. 31 U.K. Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 32 Germany
FIG. 33 Germany Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 34 France
FIG. 35 France Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 36 Spain
FIG. 37 Spain Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 38 Italy
FIG. 39 Italy Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 40 Russia
FIG. 41 Russia Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 42 Asia Pacific
FIG. 43 Asia Pacific Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 44 Japan
FIG. 45 Japan Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 46 China
FIG. 47 China Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 48 India
FIG. 49 India Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 50 South Korea
FIG. 51 South Korea Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 52 Singapore
FIG. 53 Singapore Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 54 Australia
FIG. 55 Australia Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 56 Latin America
FIG. 57 Latin America Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 58 Brazil
FIG. 59 Brazil Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 60 Mexico
FIG. 61 Mexico Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 62 Argentina
FIG. 63 Argentina Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 64 Middle East & Africa
FIG. 65 Middle East & Africa Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 66 South Africa
FIG. 67 South Africa Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 68 UAE
FIG. 69 UAE Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 70 Saudi Arabia
FIG. 71 Saudi Arabia Market Estimates and Forecast, 2016 - 2027 (USD Million)
FIG. 72 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
FIG. 73 Competitive Dashboard Analysis
FIG. 74 Market Differentiators
Note: Product cover images may vary from those shown
3 of 4
  • Sanofi
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll